Nanomi B.V., the Dutch subsidiary of global pharmaceutical leader Lupin Limited, has been honored with the prestigious CMO Award for Life Science Leadership in Drug Delivery during the Drug, Chemical and Associated Technologies Association (DCAT) week held in New York. This recognition marks a significant milestone in the company’s journey toward transforming pharmaceutical care through innovative drug delivery solutions.
Award Recognition at DCAT Week
The announcement was made during one of the pharmaceutical industry’s most influential gatherings, where leading contract manufacturing organizations and pharmaceutical innovators convene to showcase advancements in drug development and manufacturing. Nanomi’s achievement stands out as a testament to its dedication to excellence in an increasingly competitive global pharmaceutical landscape.
The CMO Award for Life Science Leadership specifically recognizes companies that demonstrate exceptional capabilities in advancing drug delivery technologies. This category highlights organizations that push the boundaries of pharmaceutical science, developing novel approaches that enhance medication effectiveness, improve patient compliance, and optimize therapeutic outcomes.
Pioneering Drug Delivery Innovation
Nanomi’s pioneering approach in drug delivery has established new industry benchmarks, combining cutting-edge science with practical applications that address real-world healthcare challenges. The company’s innovative methodologies focus on developing sophisticated delivery systems that ensure medications reach their intended targets with maximum efficacy and minimal side effects.
This award serves as both recognition of past achievements and motivation to continue the mission of revolutionizing healthcare through advanced pharmaceutical technologies. Nanomi’s work in drug delivery encompasses multiple therapeutic areas, leveraging state-of-the-art formulation technologies to create solutions that meet the evolving needs of patients and healthcare providers worldwide.
Industry Leadership and Commitment to Excellence
Dr. Shahin Fesharaki, Global Chief Scientific Officer at Lupin, emphasized the significance of this recognition: “This recognition underscores our dedication to advancing science and highlights Nanomi’s pioneering efforts in drug delivery. We remain committed to innovation that enables the delivery of high-quality medicines that significantly improve patient outcomes.”
The award reflects Nanomi’s consistent focus on research and development, quality manufacturing practices, and its ability to translate scientific innovations into tangible healthcare benefits. The company’s success demonstrates how strategic investment in pharmaceutical research combined with operational excellence can create meaningful impact in the life sciences sector.
About CMO Leadership Awards
Established in 2011, the CMO Leadership Awards represent one of the pharmaceutical industry’s most respected recognition programs. Presented jointly by Outsourced Pharma and Life Science Connect, with research conducted by Orientation Marketing, these awards identify and celebrate top outsourcing partners based on comprehensive feedback from sponsor companies that outsource manufacturing operations.
The selection process involves rigorous evaluation of contract manufacturing organizations across multiple criteria, including technical capabilities, quality systems, regulatory compliance, innovation, and customer satisfaction. This year marks a significant evolution in the awards program, as it is the first year that the CMO Leadership Award incorporates a juried selection process, adding an additional layer of credibility and prestige to the recognition.
About Lupin Limited
Lupin Limited stands as a global pharmaceutical leader headquartered in Mumbai, India, with an extensive distribution network spanning over 100 markets worldwide. The company has established itself as a trusted name in pharmaceutical manufacturing, specializing in a diverse portfolio that includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Healthcare professionals and consumers across the globe rely on Lupin’s products, and the company maintains strong market positions in both India and the United States across multiple therapy areas. These include respiratory care, cardiovascular health, anti-diabetic treatments, anti-infective medications, gastrointestinal therapies, central nervous system interventions, and women’s health products.
Lupin’s operational infrastructure comprises 15 state-of-the-art manufacturing sites and 7 dedicated research centers strategically located globally. This extensive network is supported by a workforce of over 23,000 dedicated professionals who contribute to the company’s mission of improving patient health outcomes worldwide.
The organization’s commitment to comprehensive healthcare solutions extends through its subsidiaries: Lupin Diagnostics, which focuses on diagnostic services; Lupin Digital Health, which leverages technology to enhance healthcare delivery; and Lupin Manufacturing Solutions, which provides specialized manufacturing capabilities for the pharmaceutical industry.
This latest recognition of Nanomi underscores Lupin’s broader strategy of fostering innovation across its global operations and reinforces its position as a leader in pharmaceutical research, development, and manufacturing excellence.
